Michael J. Dunn

With this double issue, Proteomics Clinical Applications enters its seventh year of publication. There continues to be sustained interest in biomedical applications of proteomics as is shown by the steady rise in the number of papers published in this field. According to data from PubMed/MEDLINE, the number has risen from around 700 papers in 2007, the first year of publication of Proteomics Clinical Applications, to around 1000 in 2011. Our aim continues to be to ensure that Proteomics Clinical Applications remains the premier source of information in the field of the application of proteomics to the study of human disease and translation to the clinic. In 2011 the Impact Factor of the journal rose to 1.97 and we confidently predict that we will see a further rise when the Impact Factor for 2012 is announced by ISI.

Over the last year, it has again been a pleasure to work with our two Associate Editors, Roz Banks (Leeds, UK) and Jennifer Van Eyk (Baltimore, MD, USA), together with Achim Kraus, Managing Editor of Proteomics Clinical Applications to help shape future development of the journal to ensure that it remains the leader in the field. I would also like to thank our group of Senior Editors who continue to make a major contribution to the journal by coordinating the peer review process for all of the papers submitted to their journal. As you may recall we made rather extensive changes to the Editorial Board of Proteomics Clinical Applications in January 2012 (Volume 6) and as a consequence we do not plan to make any major changes this year. Finally, I would like to express our sincere thanks to the panel of about 140 Reviewers, made up of members of the Editorial Board and other expert proteomic scientists, who have taken part in the peer review process of papers submitted to Proteomics Clinical Applications over the last 12 months. Their names can be found in the list, which appears at the end of this issue.

I would now like to inform you about some new features and organizational changes that affect Proteomics Clinical Applications. During 2012 we started a new series of articles under the general title “Personal Perspective”. The aim of this series of articles, coordinated by Roz Banks, is to provide experts in various areas of clinical proteomics the opportunity to give their personal view and critical assessment of their own area of proteomics expertise. The first five articles in this series were published during 2012 in Volume 6 of the journal [1-5]. Another new Section that we launched in Volume 6 (2012) of Proteomics Clinical Applications is called “Commentary”. The idea of these short contributions is that they will refer to another scientific article published in the same issue of the journal and which has been identified as of being of outstanding scientific quality. During the on-line peer review process, Reviewers are asked to identify articles that they consider deserve to be highlighted in this way. Normally, the Reviewer identifying such an article is then invited to write a Commentary that will be published in the same issue of Proteomics Clinical Applications as the original scientific article. The first of these Commentaries was published in the journal in August 2012 [6]. I would encourage Reviewers participating in the peer review process for Proteomics Clinical Applications to be pro-active in bringing articles to our attention that they consider to be worthy of featuring with an accompanying Commentary.

As of January 2013, we are publishing a new set of Instructions to Authors for Proteomics Clinical Applications that includes some additions and amendments. Authors interested in submitting a manuscript to the journal are urged to consult carefully the current Instructions to Authors that can be found online. The current version of the Instructions to Authors is in HTML format with hyperlinks to different sections or other pages and can be seen at:

Another noteworthy change has been made concerning the selection of Reviewers for the peer review process during online submission of manuscripts at At Section four during article submission Authors have always been given the opportunity to nominate “preferred” and “non-preferred” Reviewers. In addition, it is now mandatory for Authors to select as “preferred reviewer” two candidates from the journal's Editors and Members of the Editorial Board whose fields of expertise are closest to the topic of the paper. Information about the fields of expertise of the Editors and the Members of the Editorial Board is available online as a compiled list. Authors will continue to have the opportunity to suggest additional potential reviewers or name non-preferred reviewers.

We will continue our policy of producing Special Issues devoted to collections of papers describing important and emerging areas of clinical proteomics. In Volume 7 we will publish Special Issues on Proteomic Analysis of Formalin Fixed Tissue (Editors: Jenifer Van Eyk and Roz Banks), Cancer Proteomics (Editors: O. John Semmes and Thomas Conrads), Vascular Proteomics (Editor: Manuel Mayr), Glyco-markers of Disease (Editors: Naoyuki Taniguchi and Michael Pierce), and Animal Model Systems for Proteomics (Emoke Bendixen). In addition, we are continuing our tradition of having an annual issue devoted to reviews of hot topics in clinical proteomics, and these articles are published in this current issue of the journal. We are already planning the Reviews issue of Proteomics Clinical Applications for Volume 8 (2014) – see the Call for Reviews published in this issue.

The content that used to appear on the “goPROTEOMICS” web portal has now been fully integrated into the homepages of PROTEOMICS and Proteomics Clinical Applications in Wiley Online Library. This content continues to be maintained by our Web Editor, Christine Mayer and includes Book Reviews, Cover Gallery, Meeting Reports, and Viewpoint Forum. In addition, the Meetings Diary contains information on some 300 meetings and courses in the fields of proteomics and genomics and features an interactive calendar, map views and a useful filter function. To access these features, visit the Proteomics Clinical Applications home page ( and select items from the menu “Special Features”.

Finally, I would like to thank the Associate Editors, Senior Editors, Editors of Special Issues, the Editorial Board, and in particular the Managing Editor, Achim Kraus, and his team in the Editorial Office for their efforts over the last year to maintain Proteomics Clinical Applications as the most comprehensive journal in the field. I hope that researchers will continue to choose Proteomics Clinical Applications as the journal in which to publish the results of their research. Finally, I would like to thank you, the readers, for your continued support of Proteomics Clinical Applications and hope that you will find much to stimulate and interest you in Proteomics Clinical Applications during 2013.


Michael J. Dunn



  1. Top of page
  2. References